poster data from ash, page-4

as a long time supporter and holder am delighted to see more data

The pivotal trials are key - most indications look like there will be excellent results - but you never can tell until they are in

Was heartened to see licensing deals for new oncology drugs now in the billions (sign up to Fierce Biotech or BIO smart brief for excellent daily updates on the industry)

I think CXS will be in line for an excellent deal with Pfizer, maybe GSK...

best other licensing takeover target still have to be BNO - earlier stage compound - but if I was a big pharma I'd take it out at 1.20 a share so no other big pharma got it